Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21881601 | 1.00 | PTPN1 (0.53) | PTPN1NR1H2NR1H3UCHL1HSD11B1 | |
| SCHEMBL1202987 | 0.91 | PTPN1 (0.53) | PTPN1NR1H2NR1H3UCHL1HSD11B1 | |
| SCHEMBL20483181 | 0.87 | PTPN1 (0.53) | PTPN1NR1H2NR1H3UCHL1HDAC8 | |
| SCHEMBL30069424 | 0.87 | PTPN1 (0.53) | PTPN1NR1H2NR1H3UCHL1HDAC8 | |
| SCHEMBL16271289 | 0.87 | PTPN1 (0.53) | PTPN1NR1H2NR1H3UCHL1HDAC8 | |
| SCHEMBL30069422 | 0.87 | PTPN1 (0.53) | PTPN1NR1H2NR1H3UCHL1HDAC8 | |
| SCHEMBL21490343 | 0.84 | PTPN1 (0.65) | PTPN1NR1H2NR1H3HDAC8 | |
| SCHEMBL2737917 | 0.84 | PTPN1 (0.65) | PTPN1NR1H2NR1H3HDAC8 | |
| SCHEMBL29443079 | 0.84 | PTPN1 (0.65) | PTPN1NR1H2NR1H3HDAC8 | |
| SCHEMBL20482760 | 0.83 | PTPN1 (0.49) | PTPN1NR1H2NR1H3UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200609-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |